US · IDXX
IDEXX Laboratories, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Westbrook, ME 04092
- Website
- idexx.com
Price · as of 2025-12-31
$567.46
Market cap 52.44B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $432.76 | -23.74% |
| Intrinsic Value(DCF) | $392.03 | -30.91% |
| Graham-Dodd Method(GD) | $81.01 | -85.72% |
| Graham Formula(GF) | $239.13 | -57.86% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $42.54 | $53.73 | $9.85 | $10.35 | $25.75 |
| 2012 | $45.73 | $56.52 | $8.41 | $12.30 | $22.79 |
| 2013 | $63.37 | $63.33 | $6.99 | $12.01 | $25.18 |
| 2014 | $74.50 | $65.34 | $3.51 | $8.42 | $28.34 |
| 2015 | $78.15 | $64.83 | $5.66 | $7.53 | $32.34 |
| 2016 | $150.28 | $94.96 | $25.58 | $9.18 | $45.68 |
| 2017 | $203.17 | $123.15 | $58.94 | $12.10 | $55.92 |
| 2018 | $201.74 | $135.20 | $93.48 | $19.12 | $86.77 |
| 2019 | $249.89 | $162.92 | $97.23 | $24.11 | $82.19 |
| 2020 | $497.75 | $298.48 | $158.45 | $38.64 | $136.28 |
| 2021 | $498.08 | $318.61 | $238.07 | $47.59 | $228.29 |
| 2022 | $454.86 | $271.31 | $148.26 | $43.56 | $103.31 |
| 2023 | $561.41 | $363.67 | $168.88 | $64.33 | $168.34 |
| 2024 | $430.12 | $325.11 | $88.41 | $68.26 | $153.44 |
| 2025 | $636.70 | $432.76 | $144.30 | $81.01 | $239.13 |
AI valuation
Our deep-learning model estimates IDEXX Laboratories, Inc.'s (IDXX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $432.76
- Current price
- $567.46
- AI upside
- -23.74%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$392.03
-30.91% upside
Graham-Dodd
$81.01
-85.72% upside
Graham Formula
$239.13
-57.86% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IDXX | IDEXX Laboratories, Inc. | $567.46 | 52.44B | -24% | -31% | -86% | -58% | 48.13 | 31.77 | 11.85 | 35.33 | 213.11 | 47.15 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 2259.00% | 1042.00% | 3199.00% | 2.07% | 1.03 | 43.92% | 0.00% | 0.00% | 2.39% | 38.16 | 49.26 | 12.06 | 22.89 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALNY | Alnylam Pharmaceuticals, … | $332.92 | 44.15B | +155% | +6,378% | -95% | -49% | 135.73 | 53.96 | 11.47 | 73.50 | — | 53.96 | 81.77% | 13.51% | 8.45% | 73.28% | -134.35% | 6.82% | 1.62 | 1.99 | 2.76 | 2.51 | -0.68 | -20688.00% | 6519.00% | -119273.00% | 1.09% | 0.36 | -128.40% | 0.00% | 0.00% | 5.06% | 81.65 | 88.00 | 11.03 | 5.93 |
| ARGX | argenx SE | $766.92 | 47.46B | -54% | +3,767% | -79% | +51% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| COR | Cencora, Inc. | $372.14 | 72.39B | -33% | -64% | — | -63% | 41.92 | 43.58 | 0.20 | 19.29 | 734.06 | -4.12 | 3.16% | 1.14% | 0.48% | 145.58% | 42.46% | 2.18% | 7.13 | 8.69 | 0.90 | 0.51 | 1.70 | 571.00% | 931.00% | 699.00% | 4.88% | 0.07 | 53.77% | 0.67% | 27.90% | 1.33% | 19.76 | 22.47 | 0.22 | 4.91 |
| EW | Edwards Lifesciences Corp… | $86.47 | 50.77B | -6% | -55% | -72% | -59% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| VEEV | Veeva Systems Inc. | $182.01 | 29.92B | +3% | +13% | -70% | -43% | 49.42 | 6.05 | 12.85 | 41.34 | 144.65 | 6.60 | 74.53% | 25.17% | 26.00% | 13.63% | 75.08% | 10.78% | 0.01 | — | 4.51 | 4.44 | -1.43 | 3416.00% | 1620.00% | 2083.00% | 3.03% | 0.78 | 149.51% | 0.00% | 0.00% | 1.12% | 43.70 | 28.25 | 11.00 | 16.19 |
| ZTS | Zoetis Inc. | $131.10 | 57.77B | -7% | -40% | -99% | -53% | 21.39 | 17.17 | 6.04 | 15.82 | 212.77 | -131.77 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 1005.00% | 228.00% | -65.00% | 3.99% | 1.30 | 22.78% | 1.55% | 33.30% | 7.21% | 17.89 | 28.19 | 6.80 | 5.80 |
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
- CEO
- Jonathan J. Mazelsky
- Employees
- 11K
- Beta
- 1.66
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($392.03 ÷ $567.46) − 1 = -30.91% (DCF, example).